Endurance Wealth Management’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Endurance Wealth Management’s Portfolio KLDO Stock Details KLDO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,000	Closed	-$2K	–	659
2022 Q1	$2K	Hold	1,000	–	–	﹤0.01%	618
2021 Q4	$2K	Buy	+1,000	New	+$4.07K	﹤0.01%	602
2021 Q3	–	Sell	-1,000	Closed	-$5K	–	658
2021 Q2	$5K	Hold	1,000	–	–	﹤0.01%	563
2021 Q1	$8K	Buy	+1,000	New	+$10.9K	﹤0.01%	553

Other funds holding KLDO

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Endurance Wealth Management's KLDO Position: Q2 2022 in Review

Endurance Wealth Management sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2022, closing a stake of 1,000 shares — an estimated $2K sold.

Endurance Wealth Management first reported a position in KLDO in Q1 2021 and held it in 4 quarters. The position peaked at $8K in Q1 2021. 3 funds tracked by Wall St. Rank hold KLDO as of Q2 2022.

Endurance Wealth Management reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Endurance Wealth Management sold 1,000 Kaleido Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $2K.
Endurance Wealth Management first reported a position in Kaleido Biosciences, Inc. Common Stock in Q1 2021 and held it in 4 quarters.
Endurance Wealth Management's Kaleido Biosciences, Inc. Common Stock position peaked at $8K in Q1 2021.
3 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2022.

Based on Endurance Wealth Management's 13F filing for Q2 2022, filed 20 Jul 2022.